PhoreMost Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$58.8M
- Investors
-
17
PhoreMost General Information
Description
Operator of a drug target identification and drug discovery company intended to identify new targets or drugs for future therapy. The company's platform provides cryptic druggable sites in the human genome and directly links them to useful therapeutic functions in a live-cell context and then uses these functionally validated protein fragments to inform the design of small molecule drugs with the same shape, enabling medical practitioners to continue the pipeline of highly validated first-in-class drug discovery programs for out-licensing to pharma.
Contact Information
Website
www.phoremost.comCorporate Office
- Unit 7, The Works
- Unity Campus
- Pampisford CB22 3FT
- England, United Kingdom
Corporate Office
- Unit 7, The Works
- Unity Campus
- Pampisford CB22 3FT
- England, United Kingdom
PhoreMost Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 10-Sep-2024 | $58.8M | Completed | Pre-Clinical Trials | ||
| 6. Early Stage VC (Series A) | 30-Apr-2018 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 27-Apr-2018 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC | 03-Mar-2017 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 13-May-2015 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 11-Mar-2015 | $6.12M | $6.12M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Apr-2014 | Completed | Startup |
PhoreMost Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| A1 Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | ||||||||
| A Ordinary | 46,700 | $0.001307 | $55.95 | $55.95 | 1x | $55.95 | 7.83% | |
| A Ordinary | 65,311 | $0.001307 | $50.81 | $50.81 | 1x | $50.81 | 10.96% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
PhoreMost Comparisons
Industry
Financing
Details
PhoreMost Competitors (68)
One of PhoreMost’s 68 competitors is Ncardia, a Venture Capital-Backed company based in Leiden, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ncardia | Venture Capital-Backed | Leiden, Netherlands | ||||
| Cyclenium Pharma | Corporate Backed or Acquired | Montreal, Canada | ||||
| Integral Molecular | Private Debt Financed | Philadelphia, PA | ||||
| Compass Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Circle Pharma | Venture Capital-Backed | South San Francisco, CA |
PhoreMost Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
PhoreMost Patents
PhoreMost Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202407128-D0 | Methods of protein engineering and functional screening | Inactive | 20-May-2024 | ||
| GB-202319002-D0 | Methods of protein engineering and functional screening | Inactive | 13-Dec-2023 | ||
| GB-202314894-D0 | Methods of protein engineering and functional screening | Inactive | 28-Sep-2023 | ||
| GB-202111193-D0 | Pharmaceutical compounds | Inactive | 03-Aug-2021 | ||
| GB-202110820-D0 | Targeted protein degradation | Inactive | 28-Jul-2021 |
PhoreMost Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PhoreMost Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 5Y Capital | Venture Capital | Minority | ||
| Astellas Venture Management | Corporate Venture Capital | Minority | ||
| BGF (Financial Services) | Growth/Expansion | Minority | ||
| Meltwind Advisory | Venture Capital | Minority | ||
| Trend Investment Group | Venture Capital | Minority |
PhoreMost FAQs
-
When was PhoreMost founded?
PhoreMost was founded in 2014.
-
Where is PhoreMost headquartered?
PhoreMost is headquartered in Pampisford, United Kingdom.
-
What is the size of PhoreMost?
PhoreMost has 50 total employees.
-
What industry is PhoreMost in?
PhoreMost’s primary industry is Biotechnology.
-
Is PhoreMost a private or public company?
PhoreMost is a Private company.
-
What is PhoreMost’s current revenue?
The current revenue for PhoreMost is .
-
How much funding has PhoreMost raised over time?
PhoreMost has raised $83M.
-
Who are PhoreMost’s investors?
5Y Capital, Astellas Venture Management, BGF (Financial Services), Meltwind Advisory, and Trend Investment Group are 5 of 17 investors who have invested in PhoreMost.
-
Who are PhoreMost’s competitors?
Ncardia, Cyclenium Pharma, Integral Molecular, Compass Therapeutics, and Circle Pharma are some of the 68 competitors of PhoreMost.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
